Commercialize It In U.S.

Innovent Biologics

22/10/2025 02:23

Oct 22 (Reuters) - Innovent Biologics Inc 1801.HK:

INNOVENT AND TAKEDA WILL CO-DEVELOP IBI363 PD-1/IL-2Α-BIAS) GLOBALLY AND CO-COMMERCIALIZE IT IN U.S.

WILL RECEIVE $1.2 BILLION UPFRONT PAYMENT, INCLUDING STRATEGIC EQUITY INVESTMENT OF $100 MILLION BY WAY OF SUBSCRIPTION

CO ALSO ELIGIBLE FOR POTENTIAL MILESTONES TOTALING UP TO $10.2 BILLION

Further company coverage: 1801.HK

 ((Reuters.Briefs@thomsonreuters.com;))